Sector
PharmaceuticalsOpen
₹11.91Prev. Close
₹12.57Turnover(Lac.)
₹53.07Day's High
₹12.49Day's Low
₹11.1552 Week's High
₹2952 Week's Low
₹11.41Book Value
₹7.62Face Value
₹1Mkt Cap (₹ Cr.)
274.53P/E
17.46EPS
0.72Divi. Yield
0Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
---|---|---|---|---|
Equity Capital | 28.46 | 18.02 | 12.65 | 12.65 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 142.3 | 61 | 31.35 | 27.24 |
Net Worth | 170.76 | 79.02 | 44 | 39.89 |
Minority Interest |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Revenue | 59.64 | 55.61 | 55.8 | 43.77 |
yoy growth (%) | 7.24 | -0.33 | 27.46 | 4.46 |
Raw materials | -35.71 | -33.62 | -32.69 | -26.73 |
As % of sales | 59.88 | 60.44 | 58.59 | 61.06 |
Employee costs | -7.2 | -6.81 | -6.12 | -5.54 |
Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Profit before tax | 5.43 | 2.43 | 3.02 | 1.44 |
Depreciation | -0.88 | -1 | -0.98 | -0.92 |
Tax paid | -1.02 | -0.69 | -0.8 | -0.61 |
Working capital | 6.89 | 2.82 | 4.16 | -0.74 |
Other operating items |
Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 7.24 | -0.33 | 27.46 | 4.46 |
Op profit growth | 101.2 | -19.28 | 83.47 | -51.56 |
EBIT growth | 93.42 | -16.42 | 75.72 | -42.87 |
Net profit growth | 117.53 | -16.4 | 165.71 | -69.09 |
Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
---|---|---|---|---|---|
Gross Sales | 86.71 | 65.6 | 61.21 | 59.65 | 55.62 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 86.71 | 65.6 | 61.21 | 59.65 | 55.62 |
Other Operating Income | 4.91 | 3.95 | 1.38 | 0.52 | 0 |
Other Income | 0 | 0 | 0 | 0 | 1.06 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,744.85 | 132.89 | 4,18,647.96 | 1,181.05 | 0.77 | 5,985.33 | 98.33 |
Divis Laboratories Ltd DIVISLAB | 6,001.1 | 76.85 | 1,59,310.35 | 594 | 0.5 | 2,297 | 513.62 |
Cipla Ltd CIPLA | 1,478.5 | 25.66 | 1,19,409.63 | 1,438.15 | 0.88 | 4,134.87 | 360.72 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,137.55 | 58.21 | 1,06,184.18 | 485 | 0.89 | 2,330 | 222.38 |
Mankind Pharma Ltd MANKIND | 2,413.35 | 51.49 | 99,569.64 | 416.38 | 0 | 2,396.57 | 334.17 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman & Managing Director
Arihant Baid
Independent Director
A S Nageswar Rao
Non Executive Director
A Ranga Rao Pantulu
Non Executive Director
S Ch Dharma Rao
Independent Director
Dilip Raj Singhvi
Independent Director
Shilpa Bung
Company Sec. & Compli. Officer
Dinesh Kumar Kejriwal.
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Gennex Laboratories Ltd
Summary
Gennex Laboratories Limited (formerly Prudential Pharmaceuticals Limited) was incorporated on June 25, 1985. The Company got converted into a Public Limited Company and the name was changed from Prudential Pharmaceuticals Limited to Gennex Laboratories Limited in 2007.The Company is one of the leading manufacturers and exporters of Active pharmaceutical ingredients and Intermediates. It is engaged in manufacturing and marketing of bulk drugs and intermediates. Gennex is among the leading Vertically Integrated pharmaceutical companies in India and has a robust product portfolio spread over major product segments encompassing Expectorants, Muscle Relaxants, Analgesic and Anti Fungal. The company thrives on the strength of its exports to various countries viz. Germany, United Kingdom, Spain, Singapore, Canada, Switzerland, Iran, Bangladesh, Pakistan and Others. The Companys factory is situated at Andhra Pradesh, India. The company has a professionally managed team at every stage of its operations.During the year 2005-2006, the company implemented GMP (Good Manufacturing Practices). In 2006-07, it installed Separate Air Handling System in final drug isolation area and also in drying and packing area. Also, it implemented the CGMP in manufacturing area as per ICH & WHO Guidelines. In 2007-2008, it diversified into the business of Biotech product. The Company acquired 51% shareholding in Deccan Remedies Limited and thus became the subsidiary of the Company in 2023.
Read More
The Gennex Laboratories Ltd shares price on BOMBAY STOCK EXCHANGE (BSE) is ₹12.07 today.
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Gennex Laboratories Ltd is ₹274.53 Cr. as of 09 May ‘25
The PE and PB ratios of Gennex Laboratories Ltd is 17.46 and 1.65 as of 09 May ‘25
The 52-week high/low is the highest and lowest price at which a Gennex Laboratories Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Gennex Laboratories Ltd is ₹11.41 and ₹29 as of 09 May ‘25
Gennex Laboratories Ltd's CAGR for 5 Years at 37.26%, 3 Years at 22.07%, 1 Year at -14.20%, 6 Month at -39.71%, 3 Month at -9.11% and 1 Month at -3.60%.
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.